spironolactone has been researched along with verapamil in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (17.39) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hedman, A | 1 |
| Carr, AA; Kaesemeyer, WH; Prisant, LM | 1 |
| Dacquet, C; Mironneau, C; Mironneau, J; Rakotoarisoa, L; Sayet, I | 1 |
| Bolli, P; Brouwer, RM; Bühler, FR; Conen, D; Erné, P; Kiowski, W | 1 |
| Conradi, EC; Cowart, TD; Hughes, GS | 1 |
| Koren, G | 1 |
| Brunner, HR; Burckhardt, P; Gavras, H; Waeber, B | 1 |
| Allen, LV; Erickson, MA | 1 |
| Mandarim-de-Lacerda, CA; Meirelles Pereira, LM | 1 |
| Mandarim-de-Lacerda, CA; Pereira, LM | 1 |
| Goto, Y; Higuchi, S; Minemoto, M; Ohdo, S; Suematsu, F; Yukawa, E; Yukawa, M | 1 |
| Madeira, AC; Mandarim-de-Lacerda, CA; Pereira, LM | 1 |
| Böhm, M; Eckel, L; Grube, M; Haney, J; Jedlitschky, G; Kroemer, HK; Meissner, K; Meyer zu Schwabedissen, HE; Möritz, KU; Präger, D; Rosskopf, D | 1 |
| Catania, VA; Mottino, AD; Perdomo, VG; Rigalli, JP; Ruiz, ML; Villanueva, SS | 1 |
1 review(s) available for spironolactone and verapamil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for spironolactone and verapamil
| Article | Year |
|---|---|
Antihypertensive treatment using calcium antagonists in combination with captopril rather than diuretics.
Topics: Adult; Aged; Amiloride; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Captopril; Diuretics; Drug Therapy, Combination; Female; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Nifedipine; Nitrendipine; Proline; Renin; Renin-Angiotensin System; Spironolactone; Verapamil | 1985 |
21 other study(ies) available for spironolactone and verapamil
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Inhibition by basic drugs of digoxin secretion into human bile.
Topics: Bile; Chromatography, High Pressure Liquid; Digoxin; Drug Interactions; Humans; Probenecid; Quinidine; Quinine; Radioimmunoassay; Spironolactone; Verapamil | 1992 |
Verapamil and nifedipine in combination for the treatment of hypertrophy heart disease.
Topics: Adrenal Gland Diseases; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hyperaldosteronism; Hyperplasia; Hypertension; Male; Nifedipine; Spironolactone; Verapamil | 1991 |
Interactions of spironolactone with (+)-[3H]-isradipine and (-)-[3H]-desmethoxyverapamil binding sites in vascular smooth muscle.
Topics: Animals; Binding Sites; Calcium Channel Blockers; Cell Membrane; Horses; In Vitro Techniques; Isradipine; Ligands; Muscle, Smooth, Vascular; Portal Vein; Progesterone; Pyridines; Spironolactone; Verapamil | 1990 |
Efficacy of verapamil--hydrochlorothiazide-spironolactone therapy in hypertensive black patients.
Topics: Adult; Aged; Black People; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Posture; Spironolactone; Verapamil | 1987 |
Interaction between digoxin and commonly coadministered drugs in children.
Topics: Amiodarone; Child, Preschool; Digoxin; Drug Interactions; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Nifedipine; Quinidine; Spironolactone; Verapamil | 1985 |
Hypertension in a patient with hypercalcemia: captopril and verapamil.
Topics: Adult; Captopril; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Hyperparathyroidism; Hypertension; Proline; Spironolactone; Verapamil | 1982 |
Stability of labetalol hydrochloride, metoprolol tartrate, verapamil hydrochloride, and spironolactone with hydrochlorothiazide in extemporaneously compounded oral liquids.
Topics: Antihypertensive Agents; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Diuretics; Dosage Forms; Drug Compounding; Drug Stability; Humans; Hydrochlorothiazide; Labetalol; Metoprolol; Sodium Chloride Symporter Inhibitors; Spironolactone; Suspensions; Verapamil | 1996 |
Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Enalapril; Enzyme Inhibitors; Heart; Hypertension; Male; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Wistar; Spironolactone; Verapamil | 2000 |
Heart biometry and allometry in rats submitted to nitric oxide synthesis blockade and treatment with antihypertensive drugs.
Topics: Animals; Antihypertensive Agents; Body Weight; Enalapril; Heart; Heart Ventricles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Organ Size; Rats; Rats, Wistar; Regression Analysis; Spironolactone; Verapamil | 2001 |
Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Calcium Channel Blockers; Creatinine; Digoxin; Diltiazem; Drug Interactions; Female; Heart Failure; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Nifedipine; Pharmacoepidemiology; Regression Analysis; Reproducibility of Results; Spironolactone; Verapamil | 2002 |
Cardiomyocyte volume-weighted nuclear volume and spironolactone therapy in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cell Nucleus; Dose-Response Relationship, Drug; Enalapril; Hypertension; Male; Myocytes, Cardiac; Rats; Rats, Inbred SHR; Spironolactone; Time Factors; Verapamil | 2002 |
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Cell Line; Dogs; Endothelial Cells; Female; Genotype; Humans; Male; Methylhydrazines; Middle Aged; Myocardium; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Solute Carrier Family 22 Member 5; Spironolactone; Transfection; Verapamil | 2006 |
Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Hep G2 Cells; Humans; Mineralocorticoid Receptor Antagonists; Polymerase Chain Reaction; Pregnane X Receptor; Receptors, Steroid; Rhodamine 123; RNA, Messenger; Spironolactone; Up-Regulation; Verapamil | 2011 |